NCT06997549

Brief Summary

The study involves multiple retrospective analyses to understand the utilization of mental health treatments provided at Greenbrook and their effectiveness

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12,000

participants targeted

Target at P75+ for all trials

Timeline
116mo left

Started May 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
May 2025Dec 2035

Study Start

First participant enrolled

May 15, 2025

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

May 21, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 30, 2025

Completed
10.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2035

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2035

Last Updated

April 9, 2026

Status Verified

April 1, 2026

Enrollment Period

10.6 years

First QC Date

May 21, 2025

Last Update Submit

April 6, 2026

Conditions

DepressionOCDAnxiety Depression

Outcome Measures

Primary Outcomes (1)

  • change in clinical outcome scores from baseline to post treatment

    real-world efficacy of NeuroStar TMS as compared to Esketamine in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9

    8 weeks

Interventions

Patients treated with NeuroStar TMSDEVICE

non-invasive brain stimulation device

Also known as: TMS
Patients treated with EsketamineDRUG

nasal spray for treating depression

Also known as: spravato

Eligibility Criteria

Age5 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Individuals who received mental health treatment at a Greenbrook Center and the data is available in their database.

You may qualify if:

  • Male or female reported in database and not an invalid entry
  • Age reported and not an invalid entry
  • Treatment date in 2011 or later.

You may not qualify if:

  • Incomplete information on treatment parameters

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Neuronetics

Malvern, Pennsylvania, 19355, United States

RECRUITING

MeSH Terms

Conditions

Depression

Interventions

Esketamine

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Eleanor Cole, PhD

    Neuronetics

    STUDY DIRECTOR

Central Study Contacts

Neha Goyal

CONTACT

7635281599neha.goyal@neurostar.com

Eleanor Cole, PhD

CONTACT

415-724-7960Eleanor.cole@neurostar.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 21, 2025

First Posted

May 30, 2025

Study Start

May 15, 2025

Primary Completion (Estimated)

December 1, 2035

Study Completion (Estimated)

December 1, 2035

Last Updated

April 9, 2026

Record last verified: 2026-04

Locations

US(1)